The Securities and Exchange Commission (SEC) is proposing to make significant changes to the eligibility of issuers to utilize Securities ...
Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) ("Biodexa” or the "Company”), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with ...
Oversubscribed $225 million concurrent private investment in public equity ("PIPE") with available cash to the combined ...